Dr Jennifer Chan speaks to ecancer about the updated results, including progression-free survival by blinded independent central review (BICR) and subgroup analyses of the CABINET Trial/Alliance A021602.

This study compared cabozantinib, a multi-kinase inhibitor targeting VEGFR, c-MET, AXL, and RET, with a placebo in a phase 3 trial involving previously treated patients with advanced neuroendocrine tumours.

The results showed that cabozantinib demonstrated significant improvement in progression-free survival by blinded independent central review in extra-pancreatic neuroendocrine tumours and pancreatic neuroendocrine tumours. Adverse events were consistent with the known safety profile of cabozantinib.

Cabozantinib may be a new treatment option for patients with previously treated, advanced neuroendocrine tumours.

Adverse events were consistent with the known safety profile of cabozantinib.

Cabozantinib may be a new treatment option for patients with previously treated, advanced neuroendocrine tumours.